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PPAR-α,PP AR -β,andPPAR-γ,andRXRinconjunctionwithPGC-1αandSIRT1,activateoxidativemetabolismgenesdetermining
insulin sensitivity. In utero, hypoxia is commonly observed in Intrauterine Growth Restriction (IUGR), and reduced insulin
sensitivityisoftenobservedintheseinfantsasadults.Wesoughttoinvestigatehowchangesinoxygentensionmightdirectlyimpact
muscle PPAR regulation of oxidative genes. Following eight days in culture at 1% oxygen, C2C12 muscle myoblasts displayed a
reduction of PGC-1α,P P A R - α,a n dR X R - α mRNA, as well as CPT-1b and UCP-2 mRNA. SIRT1 and PGC-1α protein was reduced,
and PPAR-γ protein increased. The addition of a PPAR-β agonist (L165,041) for the ﬁnal 24 hours of 1% treatment resulted in
increased levels of UCP-2 mRNA and protein whereas Rosiglitazone induced SIRT1, PGC-1α,R X R - α,P P A R - α,C P T - 1 b ,a n dU C P -
2 mRNA and SIRT1 protein. Under hypoxia, Resveratrol induced SIRT1, RXR-α,P P A R - α mRNA, and PPAR-γ and UCP-2 protein.
These ﬁndings demonstrate that hypoxia alters the components of the PPAR pathway involved in muscle fatty acid oxidative gene
transcription and translation. These results have implications for understanding selective hypoxia adaptation and how it might
impact long-term muscle oxidative metabolism and insulin sensitivity.
1.Introduction
Epidemiological studies highlight an association between
low birth weight (LBW) and intrauterine growth restriction
(IUGR) and an increased risk of metabolic syndrome,
or Syndrome X, in postnatal life [1] as a result of the
early development of insulin-resistance [2, 3]. Reduced
insulin sensitivity, or insulin resistance, is present before
overt features of the metabolic syndrome are apparent
and is believed to be a critical pathophysiological event
early in the adult disease process [4]. Insulin sensitivity
is primarily determined by the responsiveness of skeletal
muscle to insulin, since up to 90% of insulin stimulated
glucose uptake takes place in this tissue. In insulin-resistant
individuals, skeletal muscle typically displays altered fatty
acid transport and oxidation, intramyocellular lipid accu-
mulation, and reduced mitochondrial oxygen uptake [5, 6].
The nuclear receptor family, the Peroxisome Proliferator-
Activated Receptors (PPARs) PPAR-α,P P A R - β/δ, and PPAR-
γ, the PPARs’ obligatory cotranscription factor, Retinoid X
Receptor (RXR), and the transcriptional coactivator PPAR-
γ,c o a c t i v a t o r - 1 α (PGC-1α), are considered essential in
generating normal skeletal muscle ﬁber type distribution,
fatty acid oxidative metabolism, and insulin sensitivity [7–
10]. Additionally, the sirtuin, SIRT1, has been proposed to
lie at the center of a regulatory loop regulating the actions of
PGC-1α and the PPARs, ultimately controlling muscle fatty
acid oxidation [11, 12].2 PPAR Research
PGC-1α levels are directly correlated with overall oxida-
tive capacity, maintaining a high number of active mito-
chondria and oxidative proteins, thereby increasing insulin
sensitivity [13]. Reduced skeletal muscle PGC-1α has been
linked to the development of insulin resistance and Type II
diabetes [14]. Muscle PGC-1α expression is dependent upon
PPAR-β/δ activity [9] and together with PPAR-α, directly
and indirectly, regulate genes involved in fatty acid transport
and oxidation [15–17]. Two of particular importance are
carnitine palmitoyltransferase 1 (CPT-1b), involved in the
mitochondrial transfer and oxidation of long-chain fatty
acids [18], and the uncoupling protein (UCP-1, -2, and -
3) family responsible for regulating mitochondrial electron
ﬂux and augmentation of mitochondrial fatty acid oxidation
[19, 20]. Altered expression of these genes is directly
correlated with insulin insensitivity, through impaired fatty
acid oxidation, intramyocellular lipid accumulation, and
mitochondrial damage [21–23].
Potential alterations to these above signaling pathways
have been highlighted in the development of insulin resis-
tance in IUGR studies [2, 3]. Low birth weight and IUGR
babies display signiﬁcant diﬀerences in measures of insulin
sensitivity as early as 2 and 7 years of age [2, 4] and clinical
outcomes consistent with peripheral insulin resistance in
early adulthood [3, 24]. Further, studies in animal IUGR
models report altered fetal and downstream genes involved
in muscle fatty acid oxidation, such as CPT-1b and the UCP
family [25], and permanent alterations in body composition,
including increased adiposity [26]. These studies suggest
that in utero programmed alterations in muscle oxidative
metabolism likely manifest themselves in postnatal life.
Near term, IUGR pregnancies commonly display reduc-
tions in oxygen and other nutrient supply to the fetus
[27, 28], as a result of a chronic failure in placental gas
and nutrient (glucose and amino acids) exchange and
function (i.e., placental insuﬃciency), with a corresponding
reduced fetal growth. Studies concerning the eﬀects of global
placental insuﬃciency upon fetal muscle development and
possible postnatal outcome are emerging, though direct
eﬀects of individual components of placental insuﬃciency,
such as hypoxia, are lacking. Hypoxia is a critical regulator
of fetal growth, independent of other nutrients [29, 30], and
molecular oxygen plays a critical role in energy homeostasis,
providing cues for modulation of gene expression. Further,
prenatal inﬂuences, such as in utero hypoxia leading to
reduced tissue oxygen supply, have been suggested to be as
important as genetics and life style factors in contributing to
the current “epidemic” of adult obesity and type-2 diabetes,
or the metabolic syndrome [1]. However, the eﬀects of
hypoxia upon the SIRT1/PGC-1α/PPAR signaling pathway
and downstream target genes are not well characterized.
Further, enhancing muscle insulin sensitivity in human and
animal models of obesity and diabetes, through the use
of insulin sensitizers, such as PPAR-β/δ agonists, and the
thiazolidinediones and SIRT1 modulators, such as Resvera-
trol, has been successful in restoring skeletal mitochondrial
regulation and insulin sensitivity [31–33]. Their eﬀects in
situations of hypoxia-induced alterations upon the machin-
ery associated with regulating insulin sensitivity are not
documented. The present study is aimed to identify speciﬁc
eﬀects of changes in oxygen tension upon the PPARs, their
r e g u l a t o r sa sw e l la sd o w n s t r e a mg e n e s ,a n dt oi n v e s t i g a t e
the regulatory programs activated by the PPAR-β agonist,
L165041, the PPAR-γ agonist, Rosiglitazone, and the positive
SIRT1 modulator, Resveratrol, in reduced oxygen tension
environments.
2.Methods andMaterials
2.1. Experimental Design. C2C12 myoblast cell line was
purchased from ATCC (Manassas, VA). The C2C12 cell line
is well established for the study of PGC-1/PPAR interactions
as well as oxidative capacity [34, 35] and has been previously
utilized in hypoxic studies [36, 37]. Cells were cultured
in DMEM supplemented with 10% fetal bovine serum to
approximately 70% conﬂuence prior to passage or diﬀerenti-
ation induction. C2C12 cells are induced to diﬀerentiate with
DMEM supplemented with 2% adult horse serum (DM).
For hypoxia studies, cells were placed in one of two (5%
or 1% oxygen) reduced oxygen regimes for up to eight days
with medium change every 48 hours. Control samples were
incubated at 21% oxygen. Hypoxia was attained by placing
appropriate cultures in an anaerobic incubator (Modular
Incubator Chamber (MIC-101) Billups-Rothberg, Del Mar,
CA)ﬂushedandﬁlledwithapredetermined oxygenmixture,
e i t h e r1 %o r5 %O 2 (with 5% CO2, balance N2). The 5%
and 1% oxygen regimes were selected as being representative
of fetal arterial oxygenation in the normal growth situation
(5%∼38Torr) and in the hypoxic fetal growth restricted
situation (1%∼8T orr) [28, 38]. While in vivo fetal muscle
cell tension would be at lower concentrations, the use of
relative concentrations is deemed to be suitable to highlight
diﬀerential eﬀects of altered oxygen tension [36]. Cells were
harvested just prior to treatment or day zero (D0), and then
attwo(D2),ﬁve(D5),andeight(D8)daysaftertheinitiation
of speciﬁc oxygen regimes for mRNA and protein analyses.
Additional experiments were conducted in which after
seven days in set oxygen regimes; diﬀerentiated myotubes
were treated with agonists for PPAR-β (L-165041; 10μM,
EMD Biosciences, Germany) [39], PPAR-γ (Rosiglitozone;
10μM, Cayman Chemical) [34], the SIRT1 activator, Resver-
atrol (50μM, EMD Biosciences) [40], or the vehicle,
DMSO. Agonist and modulator treatment concentrations
were determined according to previous reports with C2C12
preparations [34, 39, 40]. Cells were then returned to their
respective control (21% oxygen) or hypoxic (5% or 1%
oxygen) conditions, and mRNA and protein samples were
harvested 24 hours later.
2.2. Preparation of RNA and Real-Time PCR Procedures.
Total cell lysates was collected for relative mRNA quantiﬁ-
cation. Total RNA was prepared with TRIzol reagent, and
cDNAs were generated using Superscript (Life Technologies,
Inc. Burlington, Ontario) and oligo dT primer. Real-time
PCRs were performed using 20ng of diluted cDNA, 200nM
of each primer, and SYBR Green PCRmix (BioRad, Hercules,
CA, USA)) on the CFX384 real-time PCR detection systemPPAR Research 3
(Bio-Rad). A relative standard curve of pooled C2C12 cDNA
was generated (six standards prepared as 4-fold serial
dilutions) and used for quantiﬁcation of unknown sample
expression. Results were adjusted to the relative level of
Ribosomal Protein L7 (RL7) mRNA and expressed relative
to the average of the control group for each gene. Speciﬁc
primer sets and PCR conditions for mouse LOX, SIRT1,
PGC-1α,R X R - α,P P A R - α, β/δ,- γ, CPT-1b, and UCP-2
are detailed in Table 1, and speciﬁc PCR products were
sequenced to conﬁrm their identity. Target cDNA levels were
quantiﬁed utilizing iQ SYBR Green Master Mix (Bio-Rad)
according to the manufacturer’s instructions. All results were
normalized to RL7 RNA (Table 1). The relative expression
was shown as a relative fold change of the target gene to zero
using the Pfaﬄ equation [41].
2.3. Western Blot Analysis. Total cell lysates were collected
for protein determination. Protein quantity was determined
using a detergent compatible protein assay kit (Bio-Rad).
Twenty micrograms of total protein were mixed with 4x
sample buﬀer, boiled for one minute and loaded onto a
4%–12% SDS-PAGE gradient gel. After the proteins were
suﬃciently separated, they were transferred onto a PVDF
membrane (GE Healthcare, Buckinghamshire, UK). Western
blots were conducted using antibodies purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) to determine the
levels of SIRT1 (SC-15404, 1:200) or PGC-1α (SC-13067,
1:200) or PPAR-γ (SC-7196, 1:200) and from Abcam
(Cambridge, MA, USA) to determine UCP-2 (Ab67241
(1:500), with an overnight incubation at 4◦C. Blots were
incubated for one hour with a horseradish peroxidase
conjugated donkey antirabbit secondary antibody (711-035-
152, 1:10,000; Jackson ImmunoResearch Laboratories, Inc.
West Grove, PA), and speciﬁc proteins were detected using
ECLchemiluminescencesubstrate(ThermoFisherScientiﬁc,
Rockford, IL, USA). For a loading control, blots were
reprobed using a polyclonal antibody against β-tubulin (ab-
5046, 1:10,000). Western blot analysis were performed by
standard methods using enhanced chemiluminescence, as
per manufacturers instructions (Thermo Fisher Scientiﬁc)
and quantiﬁcation carried out using Quantity One software
(Bio-Rad).
2.4. Statistical Analysis. For the 8-day culture experiments,
fold diﬀerences from zero for the mRNA of the gene of
interest were generated and normalized to RL7 mRNA and
the Day 0 set as 1. Protein data were normalized on the
respective β-tubulin sample and the Day 0 sample was set
as 1. Normalcy of the mRNA and protein data were tested
with a two-tailed F test and then analyzed using One Way
ANOVA with a Tukey posttest. Data are presented as mean
values±SEM and represent 3–5 independent experiments
and a P-value <. 05 was considered statistically signiﬁcant.
For the PPAR-β/δ,- γ agonist and Resveratrol experiments,
fold diﬀerences of relative expression of the speciﬁc gene of
interest mRNA normalized to RL7 mRNA were reported.
Within diﬀerent oxygen regimes the eﬀects of treatments
(L165,041, Rosiglitazone, and Resveratrol) were evaluated by
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Figure 1: LOX mRNA in control (21% oxygen), 5%, or 1% oxygen
at collection points Day 0, 2, 5, and 8. Values represent the mean
of 3-4 experiments. Mean values±SEM. ANOVA, ∗signiﬁcant
between control time point and corresponding hypoxic time point
(P<. 05).
Student’st-test,andarepresentedasmeanvalues±SEMand
represent 3–5 independent experiments. A P-value <. 05 was
considered statistically signiﬁcant.
3. Results
3.1.MarkersofReducedOxygenTensionandPPARExpression.
To conﬁrm that the diﬀerentiated myotubes were experienc-
ing hypoxic conditions, expression of lysyl oxidase (LOX)
mRNA, an HIF-1α-induced molecular marker [42]w a s
determined. Under 1% oxygen, LOX mRNA was signiﬁ-
cantly increased over control at Day 5 (D5) and Day 8
(D8) (Figure 1). Interestingly, while LOX levels appeared to
remain elevated at D8 of 1% culture, LOX mRNA declined
to control levels in the 5% culture by D8. These data conﬁrm
the existence of a prolonged hypoxic environment in the 1%
culturesystem,withHIF-1αinductionoftargetgenessuchas
LOX occurring, though a diﬀerential response was observed
with respect to the 5% treatment.
The PPARs, the PPARs’ obligatory cotranscription factor,
RXRα, and PGC-1α, are considered essential in promoting
normal insulin sensitivity through regulating oxidative genes
[15]. Under 21% oxygen, PGC-1α and PPAR-α mRNA rose
whereasRXR-αremainedunchanged.However,PGC-1αand
PPAR-α mRNA were signiﬁcantly reduced in the 1% and
5% oxygen compared to control time points by D5 (Figures
2(a) and 2(b)). RXRα mRNA levels remained constant at
21% over the 8-day regime (Figure 2(c)), while levels were
similarly reduced as observed for PGC-1α and PPAR-α,
compared to their respective control day levels (Figure 2(c)).
Conversely,SIRT1andPPAR-β and-γ mRNA were unaltered
by oxygenation level (data not shown).
PPAR target genes include the regulators of muscle
fatty acid metabolism, such as CPT-1b and UCP-2 [15].
Similar to the rise in PGC-1α and PPAR-α mRNA over the
eight-day culture under 21% oxygen, CPT-1b and UCP-24 PPAR Research
Table 1: Gene, accession number, forward and reverse primer sequences, and calculated eﬃciencies used for real-time PCR analysis.
Gene1 Accession no. Forward primer Reverse primer Annealing
temperature Eﬃciency
SIRT1 NM 019812.2 5 -ATATTCCACGGTGCTGAGGT 5 -TCCAAATCCAGATCCTCCAG 59◦C 96.2%
PGC-1α NM 008904.2 5 -AACGATGACCCTCCTCACAC 5 -GGGTCATTTGGTGACTCTGG 59◦C 99.7%
RXR-α NM 011305.3 5 -GTTGCTTGTTTGCAATGGTG 5 -TGAGGAATATGGCCCAGAAG 59◦C 96.3%
PPAR-α NM 011144.6 5 -AACCGGAACAAATGCCAGTA 5 -CCGAATCTTTCAGGTCGTGT 59◦C 94.0%
PPAR-δ/β NM 011145.3 5 -TAGAAGCCATCCAGGACACC 5 -CCGTCTTCTTTAGCCACTGC 59◦C 95.6%
PPAR-γ NM 001127330.1 5 -CCAACTTCGGAATCAGCTCT 5 -CAACCATTGGGTCAGCTCTT 59◦C 95.1%
CPT-1b NM 009948.2 5 -CCCATGTGCTCCTACCAGAT 5 -CCTTGAAGAAGCGACCTTTG 59◦C 95.1%
UCP-2 NM 011671.4 5 -GCCTCTGGAAAGGGACTTCT 5 -AGAAGTGAAGTGGCAAGGGA 59◦C 97.7%
LOX NM 010728.2 5 -TGCTTGATGCCAACACCCA 5 -ATGCAAATCGCCTGTGGTAGC 59◦C 99.1%
RL7 NM 011291.5 5 -GGAGCTCATCTATGAGAAGGC 5 -AAGACGAAGGAGCTGCAGAAC 59◦C 99.1%
1SIRT1, PGC-1α,R X R α,P P A R - α,- β,- γ, CPT-1b, UCP-2, LOX = lysyl oxidase, and RL7 = ribosomal protein L7.
mRNA also increased. Though under both hypoxic regimes
(5% and 1%), CPT-1b mRNA was signiﬁcantly reduced
at D8 (Figure 3(a)), and UCP-2 mRNA was reduced at
D5 and D8 (Figure 3(b)). These data show that under
hypoxic conditions, PPAR target mRNAs are reduced during
myoblast diﬀerentiation.
3.2. Hypoxia Alters SIRT1, PGC-1α, and PPAR-γ Protein.
A major regulator of PGC-1α activity is the deacetylation
enzyme SIRT1 [12]. Under control 21% oxygen, SIRT1
protein level rose signiﬁcantly over the period of over the 8
days of culture, while PGC-1α protein level was consistent.
However, under 1% oxygen SIRT1 protein was signiﬁcantly
reduced compared to control at the D5 and D8 collection
points (Figure 4(a)), despite unaltered mRNA expression,
suggesting a hypoxia-induced posttranslational modiﬁcation
of SIRT1.
In addition, SIRT1 regulates another pathway of cellular
energymetabolism,controllingPPAR-γ whichplaysapivotal
role in systemic lipid and glucose homeostasis [7]. SIRT1
represses PPAR-γ activity, promoting mobilization of fatty
acids and decreasing fat accumulation [43], and PPAR-γ
represses SIRT1 [44]. In conjunction with decreased SIRT1
protein, PPAR-γ protein was increased at both 5% and 1%
oxygen, and it was signiﬁcantly elevated in both hypoxic
treatments at D8 (Figure 4(c)). These results suggest that
under hypoxia a reduced SIRT1 protein level occurs in
association with increased PPAR-γ protein levels.
3.3. PPAR-β,P P A R - γ, and SIRT1 Modulators Alter Hypoxia-
Induced Alterations. The administration of the PPARβ/δ
agonists (GW501516 and L165041) has been shown to
promote skeletal muscle fatty acid oxidation and improve
insulin sensitivity in situations of high-fat diets [39, 45].
Consistent with the D8 hypoxic culture data, RXR-α was
reduced (Figures 2(a) and 5(a)), and incubation of C2C12
myotubes with L165,041 (10μM) for 24 hours at D7 post
diﬀerentiation resulted in a signiﬁcant suppression of RXR-
α mRNA under 21% oxygen (Figure 5(a)). There were no
signiﬁcant L165,041 eﬀects upon SIRT1, PGC-1α,P P A R -
α,o rP P A R - β/δ mRNA though there were trends for
increased RXR-α (Figure 5(a)) and PPAR-γ mRNA at 1%
with L165,041 (P<. 08 and P<. 1, resp.). L165,041
stimulated increased expression of UCP-2 mRNA at both
r e d u c e do x y g e nt r e a t m e n t s( Figure 5(b)) .U n d e r5 %o r1 %
oxygen, CPT-1b mRNA was increased, though this was not
signiﬁcant (Figure 5(c)). Furthermore, protein content for
SIRT1 was decreased and PPAR-γ elevated, as previously
demonstrated under hypoxia. However, treatment with
L165,041 elicited no changes in protein at 21% and 5%
oxygen, while UCP-2 protein was elevated at 1% oxygen
when treated with L165,041 (P<. 06).
PPAR-γ stimulation,throughtheinductionof(PGC)-1α,
promotes mitochondrial biogenesis and insulin sensitivity
in several peripheral tissues including muscle tissues [13,
46]. Following seven days of diﬀerentiation under hypoxic
conditions, the PPAR-γ agonist, Rosiglitazone (10μM),
induced robust increases in SIRT1, PGC-1α, and PPAR-α
mRNAin1%oxygen(Figures6(a),6(b),and6(c)),withlittle
eﬀect under 21% or 5% oxygen. Similarly, RXR-α mRNA
u n d e r1 %o x y g e nw a si n c r e a s e d( Figure 6(d)), as was PPAR-
γ, but this was not signiﬁcant (data not shown). CPT-1b
mRNA was increased when treated with Rosiglitazone at
1% (Figure 6(e))a sw a sU C P - 2( P<. 01, data not shown),
though there was no eﬀect at 21% and 5%. Rosiglitazone
treatment had no eﬀect upon PPAR-γ protein, while SIRT1
protein was increased under 1% oxygen with Rosiglitazone
(Figure 6(f)) and UCP-2 protein displayed an increasing
trend (P<. 06).
Pharmacological modulators of SIRT1 activity such as
Resveratrol, a natural polyphenolic compound known for
its insulin sensitizing and antioxidant properties [35, 47],
signiﬁcantly increase SIRT1 activity in vitro and in vivo [48].
SIRT1 mRNA was signiﬁcantly increased in control and
hypoxic conditions (5% and 1% oxygen) with Resveratrol
treatment (50μM) for 24 hours (Figure 7(a)). Resveratrol
also had stimulatory eﬀects upon RXR-α (Figure 7(b))a n d
PPAR-α mRNA at 1% oxygen, though the latter was not
signiﬁcant (Figure 7(c), P<. 1), while no eﬀects upon PGC-
1αorPPAR-β/δ underhypoxiawereobserved.ThesechangesPPAR Research 5
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Figure 2: Fold changes in PGC-1α (a), PPAR-α (b), and RXR-α (c)
mRNA at Day 0, 2, 5, and 8 under three oxygen regimes: control
21%, 5%, and 1%. Values represent the mean of 4-5 experiments.
Mean values±SEM. ANOVA, # and ##signiﬁcant from Day 0 within
21% oxygen (P<. 05 and P<. 01); ∗signiﬁcant between respective
21% oxygen time point and corresponding hypoxic time point (P<
.05).
occurred in association with signiﬁcant decrease in PPAR-γ
mRNA under 5% oxygen and a trend under the 1% oxygen
treatment (Figure 7(d), P<. 1). Interestingly, incubation
of myotubes for 24 hours with Resveratrol, under 5% or
1% oxygen, signiﬁcantly restored decreased CPT-1b mRNA
expression at 5% oxygen and enhanced CPT-1b mRNA at
1%(Figure 7(e)).WhileResveratrolinducedasigniﬁcantrise
in UCP-2 mRNA under control oxygen conditions, hypoxia-
induced suppression of UCP-2 mRNA was not recovered
at either hypoxic treatment. Despite unaltered or reduced
mRNA, both PPAR-γ and UCP-2 protein increased at 1%
with Resveratrol (Figures 8(a) and 8(b)).
4. Discussion
Here, we show that chronic reduction of oxygen tensions to
5% and 1% oxygen for eight days induce decreased levels
of SIRT1, PGC-1α,R X R - α, and PPAR-α mRNA as well as
CPT-1b and UCP-2 mRNA in C2C12 muscle cells. These
reductions were accompanied by unaltered PPAR-β/δ and
-γ mRNA, but decreased SIRT1 and PGC-1α and elevated
PPAR-γ protein levels. Under hypoxia, it appears that aspects
ofthesealterationscaninpartbeprevented,invitro,through
PPAR-β/δ and -γ agonist and SIRT1 modulator intervention.
4.1. PGC-1α and Regulators, PPAR/RXR, Are Impaired
under Hypoxia. T h em u s c l eP G C - 1 α promoter/enhancer
sequence contains a conserved peroxisome proliferator-
activated receptor response element (PPRE) which binds
PPAR-β/δ/RXR-α heterodimers in skeletal muscle [9].
Despite PPAR-β/δ mRNA and protein being unchanged in
our hypoxic regimes, RXR-α mRNA is signiﬁcantly reduced,
in conjunction with reduced PGC-1α mRNA and protein.
Previousstudieshavedemonstratedthatexposuretohypoxia
reduces PPAR/RXR-binding activity and deactivates PPAR
activity by reducing the availability of its obligate partner
RXR-α in cardiac myocytes [49]. Further, this deactivation
appears to be HIF-1 regulated by reducing the DNA binding
of PPAR-RXR [50, 51]. In our studies, we measured the level
of LOX mRNA, which is a well-established target for HIF-1α
activity [52]. Under hypoxia, LOX mRNA was signiﬁcantly
elevated, supporting the notion of elevated HIF-1 activity
in our culture system and is likely a primary mechanism
forreducedPPAR/RXR-αandsubsequentlyreducedPGC-1α
transcription in hypoxic muscle myotubes.
4.2. Oxygen Tension Aﬀects the PGC-1α Activator SIRT1.
C2C12 SIRT1 mRNA was unaltered in chronic muscle
hypoxic culture, though SIRT1 protein was signiﬁcantly
depressed. This altered posttranslational modiﬁcation of
SIRT1 has been observed previously, where prolonged
hypoxia overcame SIRT1’s role in deacetylating HIF-1α
under normoxia and resulted in activated HIF-1α in com-
bination with reduced SIRT1 protein in hypoxia [53].
Prolonged hypoxia induces an altered redox potential [53,
54], and this leads to decreased SIRT1 expression through
increased binding of C-terminal-binding protein-1 (CtBP-
1) [55]. While there is stabilization of SIRT1 mRNA under6 PPAR Research
O2 21% 5% 1%
0258258258 (day)
∗
∗
N
o
r
m
a
l
i
z
e
d
f
o
l
d
e
x
p
r
e
s
s
i
o
n
0
2
4
6
8
##
(a) CPT-1b
O2 21% 5% 1%
0258258258 (day)
∗ ∗∗
∗
0
1
2
3
4
5
N
o
r
m
a
l
i
z
e
d
f
o
l
d
e
x
p
r
e
s
s
i
o
n
(b) UCP-2
Figure 3: Fold changes in CPT-1b (a) and UCP-2 (b) mRNA at collection points Day 0, 2, 5, and 8 under three oxygen regimes: control
21%, 5%, and 1%. Values represent the mean of 4-5 experiments. Mean values±SEM. ANOVA, ##signiﬁcant from Day 0 within 21% oxygen
(P<. 01); ∗signiﬁcant between respective 21% oxygen time point and corresponding hypoxic time point (P<. 05).
hypoxia in the current studies, overall protein synthesis
is reduced, possibly through HIF-1 actions and the phos-
phorylation and inhibition of eukaryotic initiation factor
eIF2α and inactivation of eIF4F and the mTOR kinase [56].
SIRT1isapotentNAD+-dependentproteindeacetylaseanda
central regulator of PGC-1α/PPAR muscle oxidative process
[12]. Therefore, hypoxia-induced reductions in SIRT1 levels
and possible activity will further impact upon PGC-1α
activity state and subsequent PGC-1α/PPAR target gene
activation.
4.3. Hypoxia Impairs PPAR Fatty Acid Oxidation Target
Genes. Hypoxia-induced reductions in NAD+ correspond to
reduced SIRT1 activity [55] ,r e d u c e da c t i v a t i o no fP G C -
1α and PPAR-α [12], and likely reduced transcription
of key components of fatty acid oxidation capacity. In
chronic hypoxic myotube culture, in combination with a
disrupted SIRT1/PGC-1α/RXR/PPAR pathway, target genes
CPT-1b and UCP-2 were reduced. In a similar way, hypoxic
downregulation of PPAR-α and RXR-α in cardiac culture, is
alsoassociatedwithdecreasedCPT-1bandUCP-3expression
[49, 57]. The observed reductions in C2C12 CPT-1b and
UCP-2, likely occur via hypoxia-induced deactivation of
PPAR-α by reducing the availability of its obligate partner
RXR. This has been reported to result in decreased DNA-
binding activity of PPAR-α/RXR in hypoxic myocytes and
subsequenttargetgeneexpression[49,50].Despiteunaltered
myotube PPAR-β/δ expression, PGC-1α,P P A R - α,a n dR X R -
α transcription are suppressed, suggesting PPAR-β/δ inter-
actions, alone, are insuﬃcient to maintain transcription of
CPT-1b and UCP-2 under chronic hypoxia.
In addition to PPAR-β/δ and -α, it is increasingly evident
that muscle PPAR-γ is essential for lipid and carbohydrate
metabolic homeostasis [7, 10]. PPAR-γ signaling activates
expression of a number of oxidative and insulin-sensitizing
genes including the UCPs (UCP-2 and -3), resistin, and
adiponectin [58, 59]. PPAR-γ activity is regulated by phos-
phorylation status and phosphorylation of serine residue
273 in mouse embryonic ﬁbroblasts results in a dysregu-
lation of a large number of insulin sensitizing genes [60].
Further, the use of Rosiglitazone, which impedes aspects
of PPAR-γ phosphorylation, improved indices of insulin
sensitivity [60]. On the other hand, it is interesting to
note that mutation of the other PPAR-γ phosphorylation
site, serine 112, leads to increased transdiﬀerentiation of
C2C12 myocytes into adipocytes [61]. These results suggest
a balance between phosphorylation sites may confer diﬀer-
ential PPAR-γ actions. In our prolonged hypoxic conditions,
despite elevated PPAR-γ protein, UCP-2 remained sup-
pressed, possibly due to the reduced PGC-1α/RXR-α activity
and yet to be determined hypoxia-induced alterations in
PPAR-γ phosphorylation status and hence activity.
Further, regulation of PPAR-γ occurs through SIRT1.
It has recently been reported that SIRT1 interacts with
the transcriptional corepressor NCoR, negatively regulating
PPAR-γ in white fat. This promotes mobilization of fatty
acids,asopposedtoaccumulation,whichoccursinsituations
of depressed SIRT1 [43]. If such a pathway occurs in
chronically hypoxic muscle, in conjunction with the reduced
SIRT1 activity, this interaction could be responsible for
removing SIRT1 inhibition upon PPAR-γ, resulting in the
observed increased PPAR-γ protein. Further, it is reported
that PPAR-γ exerts a negative feedback loop eﬀect upon
SIRT1 [44]. Therefore, under hypoxia, changes in muscle
PPAR-γ protein and activity and continual suppression of
SIRT1 interactions could lead to an increased adipogenic
capacity over a fatty acid oxidative state.
4.4. Recovery of Hypoxia-Induced Reductions in Oxidative
Genes. Enhancing muscle’s metabolic activity through the
use of PPAR-β/δ and PPAR-γ agonists, has been successful
in restoring skeletal mitochondrial regulation and insulinPPAR Research 7
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Figure 5: The eﬀect of PPAR-β/δ agonist (L165,041, 10μM)
treatment for 24 hours, following 7 days of diﬀerentiation under
relative oxygen regimes, 21%, 5%, and 1%. Fold expression of RXR-
α (a), UCP-2 (b), and CPT-1b (c) mRNA with (+) and without
(−) L165,041. Values represent the mean of 4-5 experiments. Mean
values±SEM. The eﬀect of L165,041 within each oxygen regime
was evaluated by Students t-test, ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001.8 PPAR Research
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Figure 7: The eﬀect of SIRT1 modulator (Resveratrol, 50μM) treatment for 24 hours, following 7 days of diﬀerentiation under relative
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without (−) Resveratrol. Values represent the mean of 4-5 experiments. Mean values±SEM. The eﬀect of Resveratrol within each oxygen
regime was evaluated by Students t-test within oxygen regime, ∗P<. 05, ∗∗P<. 01.10 PPAR Research
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Figure 9: Model of how hypoxia may induce reduced myotube fatty acid oxidation gene expression. Hypoxia-induced HIF-1α results in
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sensitivity [13, 34]. Additionally, the insulin-sensitizing
eﬀects of the polyphenol, Resveratrol, through modulation
of SIRT1/PGC-1α activity, have been highlighted as being
beneﬁcial in tackling aspects of metabolic disease [31].
PPAR-β/δ agonistsretardweightgainandpromoteskele-
tal muscle fatty acid oxidation and insulin sensitivity [45].
Under hypoxia, L165,041 treatment had minimal eﬀects
though target genes of PPAR-β/δ where activated. Similar to
L6 muscle cell studies, C2C12 UCP-2 may be an additional
target gene of PPAR-β/δ through L165,041 activation [39]
and under hypoxia, increased UCP-2 mRNA and protein
(P<. 06) results. The continuation of this response under
maintained hypoxia is to be determined.
Rosiglitazone treatment during hypoxia, on the other
hand, induced robust increases in members of the SIRT1/
PGC-1α/PPAR pathway under 1% oxygen, with little eﬀect
under 21% or 5% oxygen. These changes resulted in
increasedtargetCPT-1bandUCP-2mRNAexpressionunderPPAR Research 11
1% oxygen. Rosiglitazone-induced changes under hypoxia
are similar to the changes reported to occur when rescuing
an insulin resistant state with the related thiazolidinedione,
Pioglitazone, through induction of PGC-1α activity [13].
Further, these data suggest that Rosiglitazone may act under
hypoxia in a similar manner as reported in rescuing insulin
sensitivity in alcoholic fatty liver, through increased pharma-
cological modulation of SIRT1-AMPK signaling [62].
Under normal oxygenation and both 5% and 1% oxygen,
SRIT1 mRNA expression was increased with Resveratrol,
though protein content was unaﬀected in the time period
examined. Resveratrol speciﬁcally increases SIRT1 activity
through an allosteric interaction, resulting in the increase of
SIRT1 aﬃnity for both NAD+ and the acetylated substrate
[13, 48]. This potentially promotes an increased eﬃciency
of SIRT1 in hypoxia as indicated by target gene activation
throughincreasedCPT-1btranscriptionandincreasedtrans-
lation of UCP-2. Interestingly, however, PGC-1α mRNA was
not recovered as would be expected. In light of diﬀerential
target gene activation, Resveratrol’s primary actions in
maintained hypoxia may be promotion of selected fatty
acid oxidation genes rather than mitochondrial biogenesis
[11, 31]. Under hypoxia, it has been previously shown that
Resveratrol promotes recovery of inhibitory HIF-1α activity
and an increased PPAR-α expression in an oxygen/glucose
deprivation neuron model [63]. Intriguingly, under 1%
hypoxia, Resveratrol treatment promoted an increase in
C2C12 RXR-α, and PPAR-α mRNA. A possible mechanism
for this increase could be inhibition of hypoxia-mediated
activation of extracellular signal-regulated kinase 1/2 and
Akt, leading to a marked decrease in HIF-1α,a sr e p o r t e d
to occur in Resveratrol treated cancer cells [64, 65]. While
treatment of hypoxia-induced changes with PPAR agonists
and a SIRT1 modulator demonstrated improvements in
the SIRT1/PGC-1α/PPAR pathway and fatty acid oxidative
capacity, further work is required to fully understand the
adaptation process under continued hypoxia or following
reoxygenation.
5. Conclusions
Our present study highlights that the expression of reg-
ulators of muscle oxidative metabolism is directly altered
under reduced oxygen tension. As summarized in Figure 9,
together with reductions in PPAR/RXR mRNA expression,
hypoxia-induced HIF-1α activity impairs RXR-α/PPAR-α
transcription of PGC-1α. In combination with hypoxia-
induced PPAR-γ-impaired SIRT1 translation and possibly
reduced NAD+ availability, SIRT1 deacetylation of PGC-
1α is reduced. Further, HIF-1α-impaired PPAR-α/RXR-α
PGC-1α PPRE promoter binding results in changes in
downstream SIRT1/PGC-1α capacity. In conjunction with
altered PPAR/RXR interactions, these above changes result
in reductions of target fatty acid oxidation gene expression,
such as CPT-1b and UCP-2. Interestingly, under these
reduced oxygenation conditions, it appears that aspects of
the hypoxia-induced alterations can in part be prevented, in
vitro, through pharmacological intervention (e.g., L165,041,
Rosiglitazone, and Resveratrol). These results have impli-
cations for understanding selective hypoxia adaptation and
how it might impact long-term muscle fatty acid oxidative
metabolism and ultimately insulin sensitivity.
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